Bringing Cannabinoid Diagnostics to Personalized Cancer Care
Cannabics Pharmaceuticals Inc. (CNBX) is a US bio-pharma company dedicated to developing precision medicine personalized anti-cancer diagnostics and cannabis based treatments. It is based on Israeli R&D licensed by the Israeli Ministry of Health for scientific and clinical research. Cannabics novel technology pioneers the assimilation of precision medicine into Cannabinoid-based therapies for cancer patients, utilizing original, patented screening technologies, data management and artificial intelligence (AI).
Cannabics is developing diagnostic procedures designated for delivering precise data regarding the individual patients treatment choices for treating cancer and its side-effects . We are currently engaged in a clinical study, in Israel, on Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients. Our path to fight cancer is based on the engagement with technology tools such as High Throughput Screening Technology (HTS) on cancer cell lines and CTC drug sensitivity tests on liquid biopsies.